Abstract: The present invention relates to a trispecific antibody construct comprising (i.) a first binding domain (A), which is capable of specifically binding to a first target (A?) that is CD16A on the surface of an immune effector cell; (ii.) a second binding domain (B), which is capable of specifically binding to a second target (B?) that is another antigen on the surface of an immune effector cell, wherein said antigen is selected from the group comprising CD56, NKG2A, NKG2D, NKp30, NKp44, NKp46, NKp80, DNAM-1, SLAMF7, OX40, CD47/SIRP?, CD89, CD96, CD137, CD160, TIGIT, nectin-4, PD-1, PD-L1, LAG-3, CTLA-4, TIM-3, KIR2DL1-5, KIR3DL1-3, KIR2DS1-5 and CD3; and (iii.) a third binding domain (C), which is capable of specifically binding to a third target (C?) that is an antigen on the surface of a target cell. The present invention also relates to related nucleic acid molecules, vectors, host cells, methods of producing the antibody constructs, pharmaceutical compositions, medical uses, and kits.

Abstract: The invention relates to an anti-CD16A antigen binding protein for use in NK cell-based immunotherapy, wherein the anti-CD16A antigen binding protein is to be administered intermittently and in combination with a cytokine. In certain embodiments the antigen binding protein is a tetravalent and bispecific CD30/CD16A tandem diabody.

Abstract: The invention relates to an anti-CD16A antigen binding protein for use in NK cell-based immunotherapy, wherein the anti-CD16A antigen binding protein is to be administered intermittently and in combination with a cytokine. In certain embodiments the antigen binding protein is a tetravalent and bispecific CD30/CD16A tandem diabody.